UPDATE: PTC Therapeutics (PTCT) Initiated Neutral at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
PTC Therapeutics (PTCT) Misses Q3 EPS by 97c, Revenues Beat
October 29, 2020 5:14 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.03), $0.97 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $118.4 million versus the consensus estimate of $112.21 million.
"I am very pleased by the rapid progress that we have made this... More
